Bosutinib’s main mechanism of action and efficacy analysis

Bosutinib is an oral multi-target tyrosine kinase inhibitor, mainly used to treat patients with chronic myeloid leukemia (CML), especially those who are resistant or intolerant to other tyrosine kinase inhibitors (TKI). Its main mechanism of action is to inhibit the tyrosine kinase activity of BCR-ABL fusion protein and block abnormal signaling pathways, thereby inhibiting the proliferation of leukemia cells and promoting their apoptosis. BCR-ABL is a key driver of CML pathogenesis, and bosutinib exerts a specific anti-cancer effect by targeting this target.

In addition to inhibiting BCR-ABL, bosutinib can also inhibit Src family kinases. This feature makes its anti-cancer effect more broad-spectrum. Srckinase plays an important role in cell migration, proliferation and survival, especially in some drug resistance mechanisms. By dually inhibiting BCR-ABL and Src, bosutinib can not only overcome some resistance mutations, but also play a regulatory role in a variety of cell signaling pathways to enhance the therapeutic effect.

In terms of efficacy, clinical studies have shown that bosutinib has a good response rate in the treatment of patients with chronic phase and accelerated phaseCML. It can effectively reduce the number of leukemia cells and promote patients to achieve complete molecular remission (CMR) or cytogenetic remission (CCyR). In addition, bosutinib has shown significant efficacy in some patients who are resistant to imatinib or other second-generation TKIs, providing a new treatment option for such patients.

Overall, bosutinib has become an important therapeutic drug for patients with chronic myelogenous leukemia due to its multi-target inhibitory effect and good clinical efficacy. Its unique mechanism of action gives it an advantage in the face of drug resistance, but it also requires attention to possible side effects and individualized medication regimens to ensure optimal therapeutic effects and patient safety.

Reference materials:https://www.drugs.com/